An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Sanofi’s Tzield Approved in the US to Delay Onset of Stage 3 Type 1 Diabetes in Young Children The U.S.
Food and Drug Administration (FDA) has approved the supplemental biologic license application for Tzield (teplizumab-mzwv), expanding the indication from eight years and older to as young as one year of age to delay the onset of stage 3 type 1 diabetes in patients diagnosed with stage 2 type 1 diabetes. The approval was granted under a priority review process and is supported by one-year data from the PETITE-T1D phase 4 study (clinical study identifier: NCT05757713 ), evaluating safety and pharmacokinetics in young children.
“This approval opens an important new chapter in diabetes care for young children with stage 2 type 1 diabetes and their families,” said Kimber Simmons , MD, MS, associate professor of pediatrics at the Barbara Davis Center, Aurora, Colo . “This is especially important because these children are often at the highest risk of progressing quickly and without warning.
Endocrine News published a clinical update in Research Highlights on 24 Apr 2026.
The item focuses on Pharma Friday – April 24, 2026.
Review the original article for the full source wording and details.